# NeurAxon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuraxon

- Industry: Pharmaceuticals
- Headquarters: Mississauga, Canada
- Website: www.neuraxon.com
- Total disclosed funding: $34M
- Latest round: Series B (Aug 20, 2007)
- Investors on record: 8

## About

NeurAxon specializes in providing a marketplace for premium domain names, assisting businesses in establishing distinctive online identities through their extensive registration services and branding tools.NeurAxon is focused on offering domain registration services and branding tools to clients globally. Founded in 2004 and headquartered in Mississauga, Canada, the company has successfully completed 8 deals to date. Their most recent deal occurred on June 1, 2015, when they raised USD 1.75 mn in funding from Knight Therapeutics, bringing the total amount raised to USD 1.75 mn.NeurAxon primarily offers a marketplace for premium domain names, catering to businesses seeking unique and brandable online identities. Their core product is the domain registration service, which includes access to over 300,000 carefully curated domain names, featuring modern extensions such as .ai, .io, and .xyz. Additionally, the company provides tools for branding and naming, including AI-powered name generators and logo creation services, designed to assist startups and established enterprises in enhancing their market presence. The customer base consists of entrepreneurs, small businesses, and larger corporations across various sectors, including technology, health, and finance, looking to secure distinctive domain names to establish or redefine their online brands. NeurAxon’s products are available in numerous geographical markets, including North America, Europe, and parts of Asia, making it a versatile option for clients globally.Neuraxon generates revenue through the sale and registration of domain names, as well as by offering branding and trademark services. The company operates on a straightforward transaction structure where clients pay a one-time cost for domain purchases, which may also include optional payment plans for larger investments. Customers engage with NeurAxon primarily in a B2B context, utilizing the marketplace for domain acquisition and branding services. While specific pricing details for individual services are not disclosed, the domain registration typically involves a yearly renewal fee post-initial purchase, with the possibility of additional costs for trademark validation and filing services. The emphasis on premium domains and associated branding tools positions Neuraxon to attract a diverse clientele interested in robust online identities and intellectual property protection.NeurAxon plans to leverage recent funding of USD 1.75 mn to enhance their service offerings and expand into new geographic markets. They are focused on developing additional products related to digital branding and domain management by the end of 2023, aiming to further establish their presence in emerging markets across South America and Asia. Recent funding will support these initiatives, particularly in enhancing their technology and customer support services.

## Funding rounds

- Series B, Aug 20, 2007, $32M — Delphi Ventures, OrbiMed Advisors, Ventures West Capital, BDC Capital, Genesys Capital Management, H.I.G. BioHealth Partners, NeuroVentures
- Seed, Jul 21, 2004, $1.9M — H.I.G. Capital, Ventures West Capital, Genesys Capital Management, NeuroVentures

## Investors

- H.I.G. Capital (https://capitalatlas.ai/funds/h-i-g-capital) — Seed
- Ventures West Capital (https://capitalatlas.ai/funds/ventures-west-capital) — Seed, Series B
- Genesys Capital Management (https://capitalatlas.ai/funds/genesys-capital-management) — Seed, Series B
- NeuroVentures (https://capitalatlas.ai/funds/neuroventures) — Seed, Series B
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Series B
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series B